DUSP6/MKP-3, a specific inhibitor of MAPK1/ERK2, frequently loses its expression in primary pancreatic cancer tissues. This evidence suggests that constitutive activation of MAPK1 synergistically induced by frequent mutation of KRAS2 and the loss of function of DUSP6 plays key roles in pancreatic carcinogenesis and progression. By profiling of gene expressions associated with downregulation of MAPK1 induced by exogenous overexpression of DUSP6 in pancreatic cancer cells, we found that AURKA/STK15, the gene encoding Aurora-A kinase, which plays key roles in cellular mitosis, was among the downregulated genes along with its related genes, which included AURKB, TPX2 and CENPA. An association of expression and promoter activity of AURKA with MAPK activity was verified. Knockdown of ETS2 resulted in a reduction of AURKA expression. These results indicate that AURKA is a direct target of the MAPK pathway and that its overexpression in pancreatic cancer is induced by hyperactivation of the pathway, at least via ETS2.
Introduction
Pancreatic cancer is one of the most lethal malignancies in Japan as well as in Western countries . The survival rate for pancreatic cancer is very low, less than 10% overall , which indicates that current interventions to cure the disease are far from satisfactory. We need to develop novel efficient procedures for the prevention, diagnosis and treatment of this cancer; this desideratum leads us to intensive investigation of the molecular mechanisms of the development and progression of this disease. We have analysed genomic abnormalities in pancreatic cancer tissues and identified frequent loss of heterozygosity at 12q21-q23.1 (Kimura et al., 1996 (Kimura et al., , 1998 . We found that DUSP6/MKP-3 is a candidate tumor suppressor gene in this locus . DUSP6 is a phosphatase strictly specific for MAPK1; it forms a feedback loop for physiological regulation of MAPK activity (Keyse, 2000) . We further found that DUSP6 was frequently underexpressed in invasive carcinoma of the pancreas despite its overexpression in precancerous dysplastic lesions/pancreatic intraepithelial neoplasia (Furukawa et al., 2003 . Adenovirus-mediated exogenous overexpression of DUSP6 induced dephosphorylation of MAPK1 and subsequent growth suppression and apoptosis in pancreatic cancer cells with loss of expression of endogenous DUSP6 (Furukawa et al., 2003) . The underexpression was associated with hypermethylation of possible control regions of the gene (Xu et al., 2005) . These results indicated that constitutive activation of MAPK synergistically induced by the frequent mutation of KRAS2 and the loss of expression of DUSP6 is crucial for the growth and survival of pancreatic cancer cells . These studies prompted us to elucidate genes that influence phenotypes associated with hyperactivation of MAPK. In this study, we explored genes in pancreatic cancer cells whose expressions were altered after MAPK1 was inactivated by exogenous overexpression of DUSP6. Our investigation will surely lead to better understanding of the downstream targets of MAPK1, including AURKA.
Results

Expression profiles of DUSP6-overexpressing pancreatic cancer cells
We investigated the profiles of gene expression after adenovirus-mediated exogenous overexpression of DUSP6 in the human pancreatic cancer cell lines PCI-35 and PK-8 by using a microarray harboring 20K human genes. As we reported previously, PCI-35 lacks endogenous expression of DUSP6 but PK-8 maintains it, and the former shows constitutive activation of MAPK1 but the latter does not. The overexpression of DUSP6 induces dephosphorylation of MAPK1 and subsequent suppression of growth and induction of apoptosis, which is more remarkable in PCI-35 than in PK-8 (Furukawa et al., 2003) . Consistent with the differences in phenotypes, we found that elevations of alterations of gene expression in terms of both numbers and fold-changes were significantly higher in PCI-35 than in PK-8 (Figure 1 ). Using our criteria of cutoff expression levels, we identified 81 upregulated genes in PCI-35 and three upregulated genes in PK-8 (Supplementary Table 1 ). Of these 84 genes, 65 were involved in a variety of functional processes: eight in transportation, seven in receptor activity, six in cell proliferation, five in signal transduction, four in transcriptional regulation, four in the immune response, four in metabolism, four in the ubiquitin pathway and 23 in other functions. The functions of the remaining 19 are still unknown. We also identified 78 downregulated genes in PCI-35 and one downregulated gene in PK-8 using our criteria of cutoff expression levels (Supplementary Table 2 ). Of these 79 genes, 58 were involved in a variety of functional processes: 17 in cell cycle and mitosis, seven in DNA replication, five in the receptor signaling pathway and 29 in other functions. The functions of the remaining 21 are still to be determined. We verified the alterations of expressions in some of these genes by semiquantitative reverse transcription-PCR (RT-PCR) in the same as RNA samples of PCI-35 used in the microarray analysis, as shown in Figure 2a . We also tested the expressions of these candidate genes in MIA PaCa-2, which shows the same phenotype in response to the adenovirus-mediated overexpression of DUSP6 as that of PCI-35 (Figure 2a) . We also performed a quantitative real-time PCR assay to validate the expression of one of the downregulated genes, AURKA, further confirming the alteration of expression in cells caused by the transfections (Figure 2b ). 
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AURKA is a downstream target of MAPK1
The downregulated genes are candidate genes promoted by activated MAPK1; they could play important roles in the development and progression of pancreatic cancer. Among them, AURKA, which encodes Aurora-A kinase, was markedly downregulated along with its related genes including AURKB, TPX2 and CENPA (Supplementary Table 2 and Figure 2 ). These results led us to investigate the relationship between AURKA expression and MAPK1 activity. We and others have previously reported that AURKA is overexpressed in various pancreatic cancer cell lines (Li et al., 2003; Rojanala et al., 2004; Hata et al., 2005) . Because amplification of AURKA on 20q13.2 is known to be one of the major causes of the overexpression of AURKA (Marumoto et al., 2005) , we analysed the copy numbers of the gene in seven pancreatic cancer cell lines by fluorescence in situ hybridization (FISH). These results are summarized in Table 1 . Although MIA PaCa-2, PCI-35 and PK-9 showed very high levels of expression (Figure 3a) , no increase in copy number was evident. We employed MIA PaCa-2 and PCI-35 for further analysis as AURKA-overexpressed representative cells. The microarray result indicated an increase in AURKA transcription by active MAPK, which was verified by the semi-quantitative analysis as well as by the quantitative real-time PCR assay (Figure 2a and b).
To determine whether the transcriptional repression was associated with inactivation of MAPK1 and downregulation of AURKA protein, we performed immunoblotting analyses. In these cells, MAPK1 was constitutively activated, that is, phosphorylated (see Figure 3b and c, lanes M). Because of the adenovirusmediated exogenous overexpression of DUSP6, MAPK1 was dephosphorylated and expression of AURKA was downregulated (Figure 3b ). Although the adenovirus transfection itself may cause modest downregulation of phosphorylated MAPK in PCI35, a parallel downregulation of AURKA and MAPK1 was still observed (Figure 3b ). We employed U0126, a specific inhibitor of MAP2K, to test whether downregulation of the MAPK pathway affected the expression of AURKA. As shown in Figure 3c , downregulation of the MAPK activity via inactivation of MAP2K induced underexpression of AURKA, which was evident in MIA PaCa-2, which showed almost complete suppression of MAP2K1 and MAPK1 unlike the modest downregulation in PCI35. To test whether an activation of the MAPK pathway indeed promotes expression of AURKA, we created the constitutively active MAP2K1, MAP2K1D44-51/S218E/S222E (Mansour et al., 1996) construct and transfected it into 293 cells that did not show constitutive activation of MAPK1 to observe the effects of exogenous upregulation of the MAPK pathway. As shown in Figure 3d , overexpression of the constitutively active MAP2K1 induced hyperactivation of MAPK1 and overexpression of AURKA. Overexpression of a native MAP2K1 slightly enhanced MAPK1 activation but faintly suppressed AURKA expression by an unknown mechanism. These results indicated that the expression of AURKA was promoted by activation of the MAPK pathway. To determine whether or not the transcription is directly regulated by the MAPK activity, we moved on to analyse the promoter activity of AURKA. Figure 3a) . 
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Promoter activity of AURKA associated with MAPK1 activity Tanaka et al. (2002) analysed the promoter activity of AURKA and demonstrated that the promoter region spanning between À126 and À75, which includes a specific binding site of E4TF1 located between À85 and À79 upstream of the major transcription initiation site of AURKA, plays a major role in the transcriptional regulation. Based on this information, we constructed a reporter vector harboring the regulating promoter sequence between À126 and þ 5 of AURKA and analysed its activity in MIA PaCa-2 and PCI-35. The promoter activity was evident when compared with a mutated promoter sequence targeting the consensus binding site of E4TF1, that is, CCGGAAG compared with CCTTAAG ( Figure 4a ). Notably, the substitutions involved a core binding sequence, GGAA, of the ETS family of transcription factors embedded in the consensus binding sequence. Next, we analysed the alteration of the promoter activity by inactivating the MAPK1 either by exogenous expression of DUSP6 or by U0126 treatment. We found that the activity in the cells was significantly reduced by both treatments (Figure 4b and c). These results indicated that the promoter activity of AURKA was associated with MAPK1 activity in pancreatic cancer cells.
Knockdown of ETS2 resulting in downregulation of AURKA Next we moved on to a quest for the transcription factors mediating the MAPK signal on expression of AURKA in pancreatic cancer cells. Obviously, based upon our reporter analysis, transcription factors of the ETS family were supposed to be implicated in the activity. Among the family members, it has been demonstrated that ELK1, ETS1 and ETS2 but not E4TF1 are involved in the MAPK pathway (Oikawa and Yamada, 2003) . We chose ELK1 and ETS2 as candidates for further analysis, because ETS1 was known not to be involved in the promoter activity (Tanaka et al., 2002) . We employed the RNA interference method to deplete expressions of the factors and thus to see its effect on expression of AURKA. We found that depletion of ETS2 resulted in reduction of the expression of AURKA ( Figure 5a ). Depletion of ELK1 did not alter the expression of AURKA (data not shown). We analysed a possible association of ETS2 with the promoter of AURKA by electromobility shift assay and chromatin immunoprecipitation assay, which indicated a specific association in vitro and in vivo, respectively (Figure 5b and c). These results indicated that ETS2 plays a promoting role in overexpression of AURKA in pancreatic cancer cells.
Discussion
We investigated the expression profiles in pancreatic cancer cells exogenously overexpressing DUSP6. The profiles elucidated genes involved in the phenotypes of growth suppression and apoptosis associated with the downregulation of MAPK1 that is induced by the overexpression of DUSP6. During the course of this investigation, we found that AURKA, along with its related genes, including AURKB, TPX2 and CENPA, was one of these downregulated genes in the DUSP6-overexpressed cells. We verified that the downregulation of protein expression of AURKA was associated with inactivation of MAPK1 induced by either DUSP6 overexpression or U0126 treatment. The promoter activity of AURKA was associated with MAPK activity. Moreover, we found that ETS2 was implicated in the overexpression of AURKA in pancreatic cancer cells. 
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These results indicated that AURKA is a direct target of the MAPK pathway and that its overexpression in pancreatic cancer is induced by hyperactivation of the pathway, at least via ETS2. Genes that alter their expression in response to overexpression of DUSP6 are candidates for suppression of cell proliferation and induction of apoptosis induced by the overexpression. Among them, the upregulated genes may play direct promoting roles in the suppressive proliferation and proapoptotic phenotypes. However, only a limited fraction of these genes are known to be involved in such phenotypes, including the pro-apoptotic gene PYCARD (Masumoto et al., 1999) and some genes known to be involved in negative regulation of cell proliferation, including TGFB2, RARRES3 and IFITM1 (de Martin et al., 1987; DiSepio et al., 1998; Kita et al., 2003) . Most of the upregulated genes remain to be explored for their roles in the phenotypes as well as for their upregulation mechanisms.
The downregulated genes are candidate target genes for activated MAPK1. MAPK1 is one of major effector MAPKs that is mainly involved in cell proliferation under the RAS-RAF-MAP2K cascade (Hunter, 1995) . Primary pancreatic cancer cells exclusively harbor gainof-function mutations of KRAS2 (Caldas and Kern, 1995) . A small fraction of primary pancreatic cancer cells without mutations of KRAS2 harbor gain-offunction mutations of BRAF (Calhoun et al., 2003) . Either of these mutations leads to activation of MAPK through the cascade, and, according to our previous results, underexpression of DUSP6 can synergistically exacerbate the MAPK activation . Such data indicate that the RAS-MAPK pathway plays some key roles in pancreatic carcinogenesis. MAPK1 translocates into the nucleus and activates transcription factors, which in turn induce expression of target genes (Hunter, 1995) . The current study elucidated some of these target genes; most of them have been unknown as targets of MAPK1. Among these, 30% were directly involved in DNA replication, cell cycle progression and chromosomal segregation, indicating that MAPK1 indeed promotes expressions of genes essential for cell proliferation. They included genes encoding cyclins such as CCNA2, CCNB1, CCNB2 and CCNE2 (Hunter and Pines, 1991) , kinetocore-related molecules such as AURKA, AURKB, CENPA and CENPF (Hussein and Taylor, 2002; Kunitoku et al., 2003; Marumoto et al., 2005) , microtubule-associated molecules such as TPX2 and KIF2C (Kufer et al., 2002; Hunter et al., 2003) , RRM1 encoding ribonucleotide reductase (Parker et al., 1995) , POLQ encoding DNA polymerase theta (Sharief et al., 1999) , PRIM1 encoding DNA primase (Stadlbauer et al., 1994) , MCM4 encoding DNA replication-initiation factor (Musahl et al., 1995) and RFC4 encoding DNA replication factor (Wang et al., 2000) . Genes of interest in terms of implication in cancer progression were MMP1 and EPHA2; both are associated with invasion and metastasis (Kinch and Carles-Kinch, 2003; Seiki and Yana, 2003) . ETS1 is also interesting because it encodes a transcription factor mediating transcription of some cancer-related genes and is known to be one of the downstream target genes of MAPK1 (Foulds et al., 2004) .
One of the downregulated genes that fascinated us was AURKA. AURKA encodes AURKA/STK15/ Aurora-A kinase, which is an essential molecule involved in regulating the functions of centrosomes, spindles and kinetochores and is therefore required for proper mitosis of cells (Zhou et al., 1998; Marumoto et al., 2005) . AURKA is overexpressed in various cancer cells, including pancreatic cancer, and is associated with high-grade of tumors and poor survival of patients with cancer (Sen et al., 1997; Bischoff et al., 1998; Tanner et al., 2000; Miyoshi et al., 2001; Li et al., 2003; Jeng et al., 2004; Tong et al., 2004) Electro mobility shift assay employing the in vitro transcription-translation product of ETS2 and oligonucleotide probes corresponding to (1) the wild-type sequence between -97 and -61 of AURKA, (2) the mutated sequence, (3) the wild-type sequence with excess competitive cold probe of the same wild-type sequence, (4) the wild-type sequence with excess competitive cold probe of the mutated sequence, (5) the wild-type sequence with addition of antibody for ETS2 or (6) the wild-type sequence with addition of rabbit immunoglobulin. An arrow without an asterisk indicates a binding between ETS2 and probes. Arrows with asterisks indicate the supershifted bands showing a specific binding of ETS2 on the probe. (c) Chromatin immunoprecipitation assay for association of ETS2 with the promoter of AURKA in vivo. PCR products were electrophoresed in 3% agarose gel and visualized by ethidium bromide staining. Lanes indicate the PCR products of the immunoprecipitation with (1) and (4), anti-ETS2 antibody, (2) and (5), nonspecific rabbit immunoglobulin, (3) and (6), no antibody, (7) and (8), input control and (9), negative control. Samples in (1)-(3) and (7) were prepared from PCI-35 and those in (4)- (6) and (8) were prepared from MIA PaCa-2.
The overexpression of AURKA in various human cancers is known to correlate with amplification of AURKA, which is located on 20q13.2; however, an overexpression without gene amplification is also frequently observed (Marumoto et al., 2005) . The mechanism underlying the overexpression without gene amplification is unknown. Our results indicated that AURKA was a direct downstream target of MAPK1, suggesting that the overexpression of AURKA without gene amplification may be induced by constitutive activation of MAPK1 in cancer cells. The constitutive activation of MAPK1 is frequently observed in pancreatic cancer, as we stated above, and may in turn cause frequent overexpression of AURKA without gene amplification in pancreatic cancer (Li et al., 2003; Rojanala et al., 2004) . We found that AURKA-related molecules, including AURKB, TPX2 and CENPA, were simultaneously downregulated in DUSP6-overexpressing cells. These genes play essential roles in the function of kinetochores (Marumoto et al., 2005) . Our results indicate that the expression of key molecules for the function of kinetochores may depend on MAPK activity.
We also found that ETS2 plays a promoting role in the overexpression of AURKA in pancreatic cancer cells. ETS2 is a transcription factor belonging to the ETS family of transcription factors (Oikawa and Yamada, 2003) . The factors in this family recognize GGAA as a core consensus binding motif. ETS2 is ubiquitously expressed and involved in the RAS-MAPK pathway (Foulds et al., 2004) . Our results indicate that overexpression of AURKA is mediated by ETS2, which suggests that targeting of ETS2 is a possibility for suppression of proliferation of pancreatic cancer cells.
Recently, Hata et al. (2005) demonstrated that depletion of AURKA by RNA interference in human pancreatic cancer cells resulted in marked growth suppression in vitro, abolishment of tumorigenesity in vivo and induction of sensitivity to taxanes, chemotherapeutic drugs interfering with the functions of the mitotic spindle of the cells; these results indicate the important roles of overexpression of AURKA in the development and progression of human pancreatic cancer. Our current results suggest that downregulation of the MAPK pathway can synergistically enhance the effects of depletion of AURKA and of treatment with taxanes.
The current study demonstrates that MAPK1 induces the expression of genes that play essential roles in the progression of pancreatic cancer. The RAS-MAPK cascade seems to be a promising therapeutic target. Several small molecular inhibitors of this cascade have been developed, but blockade of the upstream cascade could lead to overly wide and toxic effects (SeboltLeopold and Herrera, 2004) . It is preferential to target specific downstream effectors of the MAPK cascade for effective therapy and our current study can contribute to selection of such candidates, as we have recently demonstrated in the targeting of AURKA (Hata et al., 2005) .
Materials and methods
Cell cultures
Seven human pancreatic cancer cell lines, PK-8, PK-9, PCI-35, Panc-1, MIA PaCa-2, BxPC-3 and AsPC-1, and a line of human kidney epithelial cells transformed with adenovirus 5 DNA, 293, were obtained and cultured as described previously (Furukawa et al., 2003) . NTI-4, a normal human fibroblast cell line, was obtained from the Health Science Research Resources Bank (Osaka, Japan) and cultured according to the supplier's instructions (http://www.jhsf.or.jp/English/index_e.html).
Adenovirus infection
A replication-defective adenovirus vector harboring DUSP6-V5-His was constructed and propagated as described previously (Furukawa et al., 2003) . Cells were seeded at 1 Â 10 6 in 10 cm dishes and incubated for 24 h. The cells were counted before infection to adjust the multiplicity of infection (MOI) of the adenovirus vectors to 50. Infection was carried out as described previously (Furukawa et al., 2003) .
Microarray
We employed the CodeLink Uniset Human 20K I Bioarray System (Amersham Biosciences Corp., Piscataway, NJ, USA) harboring 19 881 human genes for profiling of gene expression. Total RNA was extracted from mock-treated (non-infected) cells and cells infected with adenovirus vectors harboring DUSP6-V5-His or LacZ using the RNeasy Midi Kit (Qiagen, Valencia, CA, USA). Biotin-labeled cRNA probes were prepared by means of the T7-linear amplification method from 1 mg of total RNA using the CodeLink Expression Assay Kit (Amersham Biosciences Corp.) according to the manufacturer's instructions. CodeLink Uniset Human 20K I Bioarray slides were hybridized with the cRNA probes at 371C for 18 h in an INNOVA 4080 shaker (New Brunswick Scientific Co. Inc., Edison, NJ, USA) according to the protocol provided by Amersham Biosciences Corp. The slides were washed, reacted with streptavidin-Cy5 (FluoroLinktCyt5labeled streptavidin, Amersham Biosciences Corp.) and then washed and dried according to the manufacturer's instructions. The slides were scanned using a GenePix 4000A scanner (Axon Instruments, Union City, CA, USA) with the laser set to 635 nm, the photomultiplier tube (PMT) voltage to 600 and the scan resolution to 10 mm. Signals in the scanned image were converted to intensity values, and the values were then normalized by dividing them by the median value using CodeLink System Software (Amersham Biosciences Corp.). GeneSpring 6.0 software (Silicon Genetics, Redwood City, CA, USA) was used for analysing data. Because the array we employed was to be probed by a method of single dye detection, the microarray hybridization was performed separately for each type of treated cells, that is, mock (nontransfected), DUSP6-transfected and LacZ-transfected. Each experiment was independently duplicated using RNA extracted from cells of different transfection experiments. Those expression data flagged as Good by the CodeLink System Software and within less than 1.00 s.d. value in two independent experiments were included in the analysis. Values of expressions in cells infected with DUSP6-V5-His or LacZ were divided by those of mock-treated cells for normalized comparison. Criteria for upregulation were defined as follows: altered expressions were 3.00-fold or higher in DUSP6-infected cells and 1.66-fold or lower in LacZ-infected cells. Criteria for downregulation were defined as follows: altered expressions Semiquantitative RT-PCR Total RNA was isolated from cultured cells using the RNeasy Midi kit (Qiagen). Complementary DNA was generated by the reverse transcription method using 10 mg of the total RNA, as described previously (Mori et al., 1997) . The semiquantitative PCR was performed according to methods described previously (Yamanaka et al., 2004) in 25 ml of reaction buffer and using the GeneAmp PCR system 9700 (Applied Biosystems, Foster City, CA, USA). The reaction buffers for TPX2, CENPA and SOX4 contained 10% dimethyl sulfoxide (DMSO). The optimized cycling conditions were determined for each gene, and the expression of TUBA1 was monitored as the control because TUBA1 was found to be a stably expressed gene throughout the experiment. Primers used in the RT-PCR reactions were 5 0 -GACTCACCATGCGTGAATGC-3 0 and 5 
Quantitative real-time PCR assay
The quantitative real-time PCR assay was performed as described previously (Xu et al., 2005) . To monitor expression of AURKA, primers of 5 0 -TAGGATACTGCTTGTTACTT-3 0 and 5 0 -CCTCCAACTGGAGCTGTA-3 0 were used for amplification and a FAM-TAMRA-labeled oligonucleotide of 5 0 -C ATCATGGACCGATCTAAAGAAAACTG-3 0 was used as a probe. To monitor expression of B2M as an internal control, primers of 5 0 -TTTCAGCAAGGACTGGTCTTT-3 0 and 5 0 -C CAAATGCGGCATCTTCAAAC-3 0 were used for amplification and a FAM-TAMRA-labeled oligonucleotide of 5 0 -CT GAAAAAGATGAGTATGCCTGCCGTGTG-3 0 was used as a probe. The reaction mixture was prepared using ABsolutet QPCR Mixes (ABgene, Epsom, UK) and the reactions were performed using the ABI PRIZM 7000 Sequence Detection System (Applied Biosystems). The experiment was independently duplicated.
Isolation of the bacterial artificial chromosome clone and fluorescence in situ hybridization A genomic clone harboring AURKA was obtained by PCRbased screening of the CITB human bacterial artificial chromosome (BAC) library (Research Genetics, Huntsville, AL, USA) as described previously (Hoshi et al., 2000) with a paired primer set of 5 0 -AGCTCTGAGACACATGGCCT-3 0 and 5 0 -TGTGTGTCTGTCCGGCAC-3 0 specific for the sequence-tagged site of RH12027 existing on the 3 0 untranslated region of AURKA. Fluorescence in situ hybridization was performed using the BAC clones b57E22 and RMC20L116 harboring the centromeric sequence of chromosome 20, as described previously .
Immunoblotting Immunoblotting was performed as described previously (Kondo et al., 1999) . Antibodies employed were a polyclonal anti-Aurora-A kinase (Trans Genic Inc., Kumamoto, Japan), a monoclonal anti-MAP kinase, activated ( 
U0126 treatment
Cells were seeded in 10-cm dishes at 1 Â 10 6 and incubated for 24 h. U0126 (MERCK, Tokyo, Japan) was dissolved into DMSO at 2 mM. The solution was diluted in appropriate culture medium at 10 mM and sterilized by filtration. The culture medium of the cells was replaced with the medium containing U0126 and then incubated for 24 h. Dimethyl sulfoxide only or no reagent was administered as the control treatments. Cells were collected and assayed. The experiment was independently duplicated.
DNA cloning
A genomic DNA fragment of the promoter sequence of AURKA was amplified from human genomic DNA by PCR using paired primers of L1, 5 0 -TTTAGATCTGGGACTGCCA CAGGTCTG-3 0 , and L4, 5 0 -TTTAAGCTTGTGATTGGTT-GACAACA-3 0 . These primers harbored BglII (L1) and HindIII (L4) sites (italicized) to facilitate cloning. The amplified product was cloned into a pGL3 basic reporter vector (Promega Corp., Madison, WI, USA) at the BglII/ HindIII sites. For site-directed mutagenesis, two independent PCR amplifications were performed using the wild-type plasmid DNA as the template, one with a paired primer set of GL2, 5 0 -CTTTATGTTTTTGGCGTCTTCCA-3 0 , and M1, 5 0 -TGGCTCCACCACTTAAGGGTTCTTAGGGAGCAAG TG-3 0 , and the other with a paired primer set of RV3, 5 0 -CTA GCAAAATAGGCTGTCCC-3 0 , and M2, 5 0 -CACTTGCTC CCTAAGAACCCTTAAGTGGTGGAGCCA-3 0 . Then, the two amplified products were mixed and amplified by PCR using the paired primer set of L1 and L4. The generated mutant fragment was cloned into pGL3 vector as described above. A cDNA encoding the entire ETS2 open reading frame was amplified from pooled cDNAs prepared from the human adult liver cDNA library (Yatsuoka et al., 2004) by PCR with the paired primer of C3, 5 0 -TTTGGATCCGGCAGGAT-GAATGATTTCGG-3 0 , and C4, 5 0 -TTTCTCGAGGTCCTCC GTGTCGGGCTGGA-3 0 . These primers harbor BamHI (C3) and XhoI (C4) sites (italicized) to facilitate cloning. The amplified product was cloned into the pcDNA3.1/V5-His vector (Invitrogen) at the BamHI/XhoI sites. A cDNA encoding the entire MAP2K1 open reading frame was amplified from pooled cDNAs prepared from the human fetal brain cDNA library (Yatsuoka et al., 2004) by PCR with the paired primer of C1, 5 0 -TTTGGATCCCCAAAATGCCCAA-GAAGAAG-3 0 , and C2, 5 0 -TTTCTCGAGGACGCCAGCA GCATGGG-3 0 . These primers also harbor BamHI (C3) and XhoI (C4) sites (underlined) to facilitate cloning. The amplified product was cloned into pcDNA3.1/V5-His vector (Invitrogen) at the BamHI/XhoI sites. The cDNAs encoding the constitutive active MAP2K1, MAP2K1D44-51/S218E/S222E, were constructed based on the pcDNA-MAP2K1 clone constructed above as described elsewhere (Mansour et al., 1996) .
Active MAP2K1 transfection into 293
A total of 1 Â 10 6 293 cells were seeded into a six-well plate and incubated for 24 h. An aliquot of 500 ng of the constructed pcDNA-MAP2K1, the constitutive active MAP2K1 (see above), or pcDNA3.1/V5-His vector was transfected by using Lipofectamine 2000 (Invitrogen) as described in the supplier's instructions. The transfected cells were incubated for 48 h and collected for the immunoblot assay. The experiment was independently duplicated.
Reporter assay
Cells were seeded into a six-well plate at 5 Â 10 4 /well and incubated for 24 h. For DUSP6 treatment, the cells were counted and infected with AdDUSP6 or AdLacZ at MOI 50. No infection was performed as the mock treatment. After a subsequent incubation for 24 h, 500 ng of the constructed pGL3 reporter plasmid (see above) and 50 ng of phRL-TK plasmid (Promega Corp.) were transfected using Lipofectamine PLUS (Invitrogen) and incubated for 24 h. For U0126 treatment, the cells were transfected with 500 ng of the constructed pGL3 plasmid and 50 ng of phRL-TK plasmid and then incubated for 24 h. U0126 dissolved in DMSO was administered at 10 mM in final concentration and subsequently incubated for 24 h. Dimethyl sulfoxide only or no reagent was administered as the control treatments. The cells were lysed in Passive Lysis Buffer (Promega Corp.) and collected. A dualluciferase assay (Promega Corp.) was performed to measure reporter activities by using Lumat LB9507 according to the supplier's instructions (Berthold Japan, Tokyo, Japan). The experiment was independently duplicated.
RNA interference
Oligonucleotides of short interference double-stranded RNAs (siRNAs) with two thymidine residues (dTdT) overhanging at the 3 0 end to knock down the expressions of ETS2, ELK1 and LMNA, including 5 0 -CAACAGGCUUGGAUUCCAU-3 0 for ETS2, 5 0 -GGCAAUGGCCACAUCAUCU-3 0 for ELK1 and 5 0 -CUGGACUUCCAGAAGAACA-3 0 for LMNA (Elbashir et al., 2001) , were purchased from Japan Bioservice (Asaka, Japan). Transfection of these siRNAs was performed as described previously (Hata et al., 2005) . The transfected cells were incubated for 48 h and collected for immunoblot assay. The experiment was independently duplicated.
Electromobility shift assay
In vitro transcription and translation were induced by using the constructed pcDNA-ETS2 with the TNT Quick Coupled Transcription/Translation System (Promega Corp.) according to the supplier's protocol. Complementary oligonucleotides corresponding to À97 and À61 of the promoter sequence of AURKA, including the consensus binding sequence for ETS family of transcription factors (indicated by italicized letters in the following sequence), were prepared as W1, 5 0 -TGG CTCCACCACTTCCGGGTTCTTAGGGAGCAAGTGC-3 0 , and W2, 5 0 -CACTTGCTCCCTAAGAACCCGGAAGTGGT GGAGCCA-3 0 , and used as probes for the wild-type sequence. The oligonucleotides of M1 and M2 described above and corresponding to the same promoter sequence with mutations of the consensus binding sequence from TTCC in W1 to TTAA in M1 and from GGAA in W2 to TTAA in M2 were used as the mutated probes. The oligonucleotides were annealed by boiling for 5 min and gradual by cooling down to room temperature. The annealed oligonucleotides were radioactively end-labeled by the reaction of T4 polynucleotide kinase with [g-32 P]ATP. The radioactivity of the labeled probe was measured with a scintillation counter and probes at the level of 3 Â 10 4 cpm were used for the reaction. A cold competitor was used at 300-fold molar excess for comparison with the labeled probe. The reactions were analysed on a 5% polyacrylamide/2.5% glycerol gel and exposed to an imaging plate for analysis with a BAS 1500 image analyzer (Fuji Photo Film Co. Ltd). For the supershift reaction, the in vitro transcription-translation product of ETS2 was mixed with 2 mg of a polyclonal anti-ETS2 antibody (C-20, Santa Cruz Biotechnology Inc.). The experiment was independently duplicated.
Chromatin immunoprecipitation
The chromatin immunoprecipitation was carried out by using a ChIP assay kit (Upstate, Charlottesville, VA, USA) according to the manufacturer's protocol. In brief, cells were fixed with 1% formalin solution, neutralized by 125 mM glycine and collected by scraping. The cells were lysed with the SDS lysis buffer provided in the kit and subjected to sonication to shear chromatin DNA to an average length of 1 kb using an Ultrasound Sonicator Bioruptor (Cosmo Bio, Tokyo, Japan). Sonicated chromatin DNA was subjected to immunoprecipitation. Antibodies used were the polyclonal anti-ETS2 antibody (C-20, Santa Cruz Biotechnology Inc.) and a nonspecific normal rabbit immunoglobulin G (Calbiochem). PCR amplification was performed in 25 ml of the reaction mixture with primers of L1 and L4 as described above. The sonicated chromatin DNA not subjected to immunoprecipitation was used as an input control.
Statistical analysis
Statistical calculations for the reporter assay employing unpaired two-tailed Student's t-test were performed by using Statview software (SAS institute Inc., Cary, NC. USA).
